An observational study in Chronic Kidney Diseases, sponsored by Ciusss de L'Est de l'Île de Montréal. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-14.
Sponsored by Ciusss de L'Est de l'Île de Montréal · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 215 studies in Renal Insufficiency, Chronic with a site in Canada — 37 open to participants now, 61 under way, 16 of them phase 3. Renal Insufficiency, Chronic · Canada.
Among the 215 studies in Renal Insufficiency, Chronic with a site in Canada, this one is the 24th largest by planned enrollment of the 41 observational ones that give a count, is one of 10 that started in 2023, is one of 41 observational ones, reaches primary completion later than 25 of the 60 other live ones, and was the 166th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →37 of the 215 studies in Renal Insufficiency, Chronic with a site in Canada are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Canada, United States, Argentina and 24 more countries
Ages 18–99
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
AstraZeneca · Sites in Canada, United States, Argentina and 34 more countries
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
215 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 35 · Phase 3 61 · Phase 4 15
First in 2002; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 420 is above the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 195 across the 173 interventional studies, 500 across the 41 observational. Of the 143 that completed or were terminated, 58 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 215 have an industry lead sponsor. The 10 most frequent:
Ciusss de L'Est de l'Île de Montréal is the lead sponsor of 90 studies on the registry; 32 are open to participants now.
Ciusss de L'Est de l'Île de Montréal has 2 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
14 of the studies in Renal Insufficiency, Chronic with a site in Canada that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT06337838Phase 3Hamilton Health Sciences CorporationBleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial | 2027-02 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 14 to your calendar (.ics) → With an account.
Among the 215 studies in Renal Insufficiency, Chronic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
For people with advanced kidney disease, deciding which type of dialysis is best can be challenging. Studies have shown that quality of life is very important to patients. It is thought that the quality of life of people receiving their dialysis at home may be better than the one of people receiving dialysis in a hospital. However, how the start of dialysis changes the quality of life of people who choose home dialysis in comparison to people choosing dialysis in a hospital is still unknown.
TRANSIT-CARE is a prospective mixed methods study following adult with advanced kidney disease who progress to dialysis and receive home or hospital-based dialysis. This study aims to examine the trajectory and change in patients' quality of life and their frailty status (health, mobility and function) before start of dialysis and up to 12-month after start. Differences between people doing home dialysis and hospital-based dialysis will be assesses taking into account people's characteristics including their gender and socio-demographics characteristics. The study will include questionnaires to measure quality of life and tools to evaluate frailty. Additionally, semi-structured interviews will be done with a diverse group of patients and caregivers before and after the initiation of dialysis to better understand their experience of transitioning to dialysis.
Home dialysis has been encouraged due to its clinical benefits and lower costs, leading to increased use in recent years, even among patients with a high comorbidity burden and frailty severity. Health-related quality of life (HRQoL) is reduced in patients receiving dialysis, although patients treated with home dialysis may have relatively better patient-reported outcome measures (PROMs), than those on in-center dialysis. As the home dialysis population expands to include patients with a high frailty severity, it is unknown if these benefits are preserved. More importantly, data lacks on how the transition to home or in-center dialysis is experienced by patients and caregivers and whether changes in HRQoL and frailty impact this experience.
Objectives
Design and Research Plan TRANSIT-CARE is a 5-year multicenter mixed-methods study of patients with advanced CKD and their caregivers across 12 Canadian centers, with active patient-partner engagement.
QUANTITATIVE Participant will be followed every 3-months (from estimated glomerular filtration rate [eGFR] \<12 mL/min/1.73m2) and up to 12-month after dialysis start (4-week, 3-, 6-,12-month).
Target recruitment: 420 patients / 165 caregivers. Dialysis modality will be defined as the chosen modality at baseline visit, and dichotomized as home dialysis (peritoneal or home hemodialysis) and in-center dialysis.
Changes in PROMs and frailty will be assessed using multivariable mixed linear spline regression analysis with each measure used as a continuous variable adjusted for baseline scores, chosen dialysis modality (exposure), dialysis start (time-dependent variable) and prespecified potential confounders.
QUALITATIVE Semi-structured interviews will be conducted with 30 patients and 30 caregivers (from three centers) before and after dialysis initiation.
Thematic analysis will be used to identify patient and caregiver perceptions of home and in-center dialysis, their reactions to dialysis initiation (e.g., feelings of empowerment or loss, life disruption) and perceived burden for caregivers.
Data integration Data from the qualitative and quantitative components will be integrated at time of analysis using tables and joint displays.
Adults followed in advanced chronic kidney disease clinics and their caregivers will be recruited from 12 academic centers across Canada
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients transitioning to home dialysis
Other: Exposure: Home dialysis or facility-hemodialysis
Patients transitioning to facility hemodialysis
Other: Exposure: Home dialysis or facility-hemodialysis
Caregivers of patients transitioning to home dialysis
Other: Exposure: Home dialysis or facility-hemodialysis
Caregivers of patients transitioning to facility hemodialysis
Other: Exposure: Home dialysis or facility-hemodialysis
Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
Change in Kidney Disease Quality of Life - 36 (KDQOL-36) - Patients
Scale from 0-100 (0=poor , 100 = excellent )
Time frame: From study inclusion until 12-months after dialysis start.
Change in 'ZARIT' burden Interview (ZBI) - Caregivers
Scale 0-88 (0=no/little burden, 88 = severe burden)
Time frame: From study inclusion until 12-months after dialysis start.
Change in Fried Frailty phenotype
5 components (slowness, weakness, weight loss, low physical activity, exhaustion) with classification as no-frail, pre-frail or frail
Time frame: From study inclusion until 12-months after dialysis start.
Change in Clinical Frailty Scale
Scale 1 (very fit) to 9 (terminally ill)
Time frame: From study inclusion until 12-months after dialysis start.
Change in Hospital Anxiety and Depression - Patients
14-item scale (7 anxiety, 7 depression) with score ≥8 used as cut-off for increased risk of depression and anxiety
Time frame: From study inclusion until 12-months after dialysis start.
Change in Short-form (SF)-36 - Caregivers
Scale from 0-100 (0=poor , 100 = excellent )
Time frame: From study inclusion until 12-months after dialysis start.
Semi-structured interviews with patients and caregivers
2 interviews with patients and caregivers
Time frame: First interview between study start and dialysis initiation / Second interview between dialysis start and up to 12-month after dialysis start.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.
Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 47 months is below that.
Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Ciusss de L'Est de l'Île de Montréal